ET-1 Promotes Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells Via the MicroRNA-489-3p /TWIST Axis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Oct 22

PMID 34675545

Citations 6

Authors

Huey-En Tzeng

Chih-Hsin Tang

Chun-Hao Tsai

Chih-Hui Chiu

Min-Huan Wu

Yun Yen

Affiliations

Soon will be listed here.

Abstract

Objective: Oral squamous cell carcinoma (OSCC) constitutes almost 90% of head and neck malignancies and has a poor prognosis. To improve the efficacy of OSCC therapy, it is of great significance to explore other therapy for OSCC. Endothelin-1 (ET-1), a potent vasoconstrictor peptide, is implicated in cancer pathogenesis. Moreover, ET-1 promotes epithelial-mesenchymal transition (EMT) during the development of human cancers. We further to found that ET-1 exposure induced EMT in human squamous cell carcinoma cell lines SCC4 and SAS, by enhancing the expression of EMT biomarkers N-cadherin and vimentin and reducing E-cadherin expression via upregulation of the transcription factor TWIST.

Materials And Methods: Cell motility was examined by migration, invasion and wound-healing assays. Quantitative real time polymerase chain reaction (q-PCR), and promoter assays confirmed the inhibitory effects of ET-1 on miRNAs expression in oral cancer cells. We demonstrate an intravenous injection model of lung metastasis followed by an advanced method for quantifying metastatic tumor using image analysis software.

Results: In addition, ET-1/ETAR reduced levels of microRNA-489-3p (miR-489-3p), a transcriptional repressor of TWIST. We have identified a novel bypass mechanism through which ET-1/ETAR are involved in TWIST signaling and downregulate miR-489-3p expression, enabling OSCC cells to acquire the EMT phenotype. Notably, ET-1 knockdown dramatically decreased levels of EMT markers and cell migration potential.

Conclusion: The role of ET-1 in OSCC progression is supported by our findings from an in vivo murine model of OSCC. ET-1 may therefore represent a novel molecular therapeutic target in OSCC metastasis.

Citing Articles

Endothelin and the tumor microenvironment: a finger in every pie.

Arndt P, Turkowski K, Cekay M, Eul B, Grimminger F, Savai R Clin Sci (Lond). 2024; 138(11):617-634.

PMID: 38785410 PMC: 11130555. DOI: 10.1042/CS20240426.

Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.

Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref A, Aljabali A Cell Mol Life Sci. 2024; 81(1):214.

PMID: 38733529 PMC: 11088560. DOI: 10.1007/s00018-024-05236-w.

Fibromodulin overexpression drives oral squamous cell carcinoma via activating downstream EGFR signaling.

Xia L, Zhang T, Yao J, Lu K, Hu Z, Gu X iScience. 2023; 26(11):108201.

PMID: 37965134 PMC: 10641260. DOI: 10.1016/j.isci.2023.108201.

Eslami M, Khazeni S, Mohammadi Khanaghah X, Asadi M, Ansari M, Garjan J Cancer Cell Int. 2023; 23(1):182.

PMID: 37635248 PMC: 10463971. DOI: 10.1186/s12935-023-03022-5.

Expression signature and molecular basis of CDH11 in OSCC detected by a combination of multiple methods.

Wei Y, Cheng X, Deng L, Dong H, Wei H, Xie C BMC Med Genomics. 2023; 16(1):70.

PMID: 37013637 PMC: 10069064. DOI: 10.1186/s12920-023-01499-7.

References

Peng Q, Cheng Y, Zhang W, Fan H, Mao Q, Xu P . circRNA_0000140 suppresses oral squamous cell carcinoma growth and metastasis by targeting miR-31 to inhibit Hippo signaling pathway. Cell Death Dis. 2020; 11(2):112. PMC: 7010827. DOI: 10.1038/s41419-020-2273-y. View

Jayanthi P, Varun B, Selvaraj J . Epithelial-mesenchymal transition in oral squamous cell carcinoma: An insight into molecular mechanisms and clinical implications. J Oral Maxillofac Pathol. 2020; 24(1):189. PMC: 7269282. DOI: 10.4103/jomfp.JOMFP_334_19. View

Uhr K, Prager-van der Smissen W, Heine A, Ozturk B, van Jaarsveld M, Boersma A . MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One. 2019; 14(5):e0216400. PMC: 6504094. DOI: 10.1371/journal.pone.0216400. View

Lemecha M, Morino K, Imamura T, Iwasaki H, Ohashi N, Ida S . MiR-494-3p regulates mitochondrial biogenesis and thermogenesis through PGC1-α signalling in beige adipocytes. Sci Rep. 2018; 8(1):15096. PMC: 6180067. DOI: 10.1038/s41598-018-33438-3. View

Chao C, Chen P, Chiou P, Hsu C, Liu P, Yang Y . Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to Twist. Clin Sci (Lond). 2019; 133(5):709-722. DOI: 10.1042/CS20180945. View

Afshar E, Hashemi-Arabi M, Salami S, Peirouvi T, Pouriran R . Screening of acetaminophen-induced alterations in epithelial-to-mesenchymal transition-related expression of microRNAs in a model of stem-like triple-negative breast cancer cells: The possible functional impacts. Gene. 2019; 702:46-55. DOI: 10.1016/j.gene.2019.02.106. View

Wu M, Chen L, Hsu H, Lin J, Lin Y, Tsai F . Endothelin-1 enhances cell migration through COX-2 up-regulation in human chondrosarcoma. Biochim Biophys Acta. 2013; 1830(6):3355-64. DOI: 10.1016/j.bbagen.2013.03.014. View

Chandavarkar V, Uma K, Sangeetha R, Mishra M . Immunomorphological patterns of cervical lymph nodes in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2015; 18(3):349-55. PMC: 4409177. DOI: 10.4103/0973-029X.151311. View

Joseph J, Harishankar M, Pillai A, Devi A . Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 2018; 80:23-32. DOI: 10.1016/j.oraloncology.2018.03.004. View

10.

Zhuo X, Luo H, Chang A, Li D, Zhao H, Zhou Q . Is overexpression of TWIST, a transcriptional factor, a prognostic biomarker of head and neck carcinoma? Evidence from fifteen studies. Sci Rep. 2015; 5:18073. PMC: 4674799. DOI: 10.1038/srep18073. View

11.

Herrmann E, Bogemann M, Bierer S, Eltze E, Hertle L, Wulfing C . The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther. 2005; 6(1):73-81. DOI: 10.1586/14737140.6.1.73. View

12.

Tang L, Li H, Gou R, Cheng G, Guo Y, Fang Y . Endothelin-1 mediated high glucose-induced epithelial-mesenchymal transition in renal tubular cells. Diabetes Res Clin Pract. 2014; 104(1):176-82. DOI: 10.1016/j.diabres.2013.12.021. View

13.

Kalyankrishna S, Grandis J . Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24(17):2666-72. DOI: 10.1200/JCO.2005.04.8306. View

14.

Su C, Tang C, Chi M, Lin C, Fong Y, Liu Y . Resistin facilitates VEGF-C-associated lymphangiogenesis by inhibiting miR-186 in human chondrosarcoma cells. Biochem Pharmacol. 2018; 154:234-242. DOI: 10.1016/j.bcp.2018.05.001. View

15.

Ankita K, Shwetha V, Vanitha S, Reddy Sujatha S, Nagaraju R, Tupakula Pavan K . Assessment of salivary endothelin-1 in patients with leukoplakia, submucous fibrosis, oral cancer and healthy individuals - a comparative study. J Stomatol Oral Maxillofac Surg. 2019; 120(4):326-331. DOI: 10.1016/j.jormas.2019.02.024. View

16.

Meng J, Chen S, Han J, Qian B, Wang X, Zhong W . Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma. Cancer Res. 2018; 78(15):4150-4162. DOI: 10.1158/0008-5472.CAN-17-3009. View

17.

Singh S, Kumar R, Kushwaha V, Bhatt M, Singh A, Mishra A . Expression of Radioresistant Gene PEG10 in OSCC Patients and Its Prognostic Significance. Asian Pac J Cancer Prev. 2017; 18(6):1513-1518. PMC: 6373826. DOI: 10.22034/APJCP.2017.18.6.1513. View

18.

Nair D, Singhvi H, Mair M, Qayyumi B, Deshmukh A, Pantvaidya G . Outcomes of surgically treated oral cancer patients at a tertiary cancer center in India. Indian J Cancer. 2018; 54(4):616-620. DOI: 10.4103/ijc.IJC_445_17. View

19.

Lin C, Lin H . Effects of surgeon and hospital volume on 5-year survival rates following oral cancer resections: the experience of an Asian country. Surgery. 2008; 143(3):343-51. DOI: 10.1016/j.surg.2007.09.033. View

20.

Zhang Y, Weinberg R . Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018; 12(4):361-373. PMC: 6186394. DOI: 10.1007/s11684-018-0656-6. View